After nearly 30 years as a Community Clinical Oncology Program (CCOP) performing vital cancer research, the North Shore-LIJ Health System (NSLIJHS) is applying to become a Community Site as part of the National Cancer Institute's NCORP Program. Since its latest CCOP renewal, the NSLIJHS research program enrolled 1,300 subjects on cancer treatment, prevention and control trials, meeting or exceeding the required annual 60 treatment and 80 control credits for each grant year. The NSLIJHS NCORP program will offer local access to and data management support for almost 300 cancer research studies open to accrual through its affiliations with Alliance, the University of Rochester Cancer Center, the Wake Forest Cancer Center, NRG Oncology and other Research Bases through the Cancer Trials Support Unit (CTSU). As the NSLIJ CCOP transitions to an NCORP Community Site, its primary goal for the grant cycle will be to enhance its multifaceted partnership with NSLIJHS Divisions and NCORP Subcomponents in order to create a network of primary care and multi-specialty health professionals, community organizations, local governments and research base organizations that will (a) conduct cancer prevention, control, and screening/post-treatment surveillance clinical trials;(b) design and conduct multi-level cancer care delivery research;(c) enhance patient and provider access to treatment and imaging clinical trials;and (d) increase the participation of minorities, women and other underserved populations across all study types and settings. The NSLIJHS NCORP will be a multidisciplinary research unit. It will include 64 medical, radiation and surgical oncologist from Nassau, Suffolk and Queens Counties in New York. An additional 34 full time support staff including ONS and SoCRA certified nurses, data managers, research coordinators, regulatory staff and others will participate at a variety of locations across the catchment area. In 2012, NSLIJHS diagnosed and/or treated over 16,000 new cancers cases and accounted for nearly 30% percent of all cancer-related inpatient and ambulatory surgery discharges in New York's Queens, Nassau and Suffolk counties.
The NSLIJ Health System's 2013 Community Health Needs Assessment identified cancer as a significant health priority in Queens, Nassau and Suffolk Counties in NYS. Research with community members and health care professionals identified increased outreach and collaboration between health care providers and local communities were effective and vital health improvement strategies.
|Gounder, Mrinal M; Mahoney, Michelle R; Van Tine, Brian A et al. (2018) Sorafenib for Advanced and Refractory Desmoid Tumors. N Engl J Med 379:2417-2428|
|Runcie, Karie; Budman, Daniel R; John, Veena et al. (2018) Bi-specific and tri-specific antibodies- the next big thing in solid tumor therapeutics. Mol Med 24:50|
|Eisfeld, Ann-Kathrin; Kohlschmidt, Jessica; Mrózek, Krzysztof et al. (2018) Mutation patterns identify adult patients with de novo acute myeloid leukemia aged 60 years or older who respond favorably to standard chemotherapy: an analysis of Alliance studies. Leukemia 32:1338-1348|
|Himelstein, Andrew L; Foster, Jared C; Khatcheressian, James L et al. (2017) Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases: A Randomized Clinical Trial. JAMA 317:48-58|
|Kimmick, Gretchen G; Major, Brittny; Clapp, Jonathan et al. (2017) Using ePrognosis to estimate 2-year all-cause mortality in older women with breast cancer: Cancer and Leukemia Group B (CALGB) 49907 and 369901 (Alliance A151503). Breast Cancer Res Treat 163:391-398|
|Basch, Ethan; Dueck, Amylou C; Rogak, Lauren J et al. (2017) Feasibility Assessment of Patient Reporting of Symptomatic Adverse Events in Multicenter Cancer Clinical Trials. JAMA Oncol 3:1043-1050|
|Uy, Geoffrey L; Mandrekar, Sumithra J; Laumann, Kristina et al. (2017) A phase 2 study incorporating sorafenib into the chemotherapy for older adults with FLT3-mutated acute myeloid leukemia: CALGB 11001. Blood Adv 1:331-340|
|Zent, Clive S; Victoria Wang, Xin; Ketterling, Rhett P et al. (2016) A phase II randomized trial comparing standard and low dose rituximab combined with alemtuzumab as initial treatment of progressive chronic lymphocytic leukemia in older patients: a trial of the ECOG-ACRIN cancer research group (E1908). Am J Hematol 91:308-12|
|Rogers, C Leland; Perry, Arie; Pugh, Stephanie et al. (2016) Pathology concordance levels for meningioma classification and grading in NRG Oncology RTOG Trial 0539. Neuro Oncol 18:565-74|
|Bhatnagar, B; Blachly, J S; Kohlschmidt, J et al. (2016) Clinical features and gene- and microRNA-expression patterns in adult acute leukemia patients with t(11;19)(q23;p13.1) and t(11;19)(q23;p13.3). Leukemia 30:1586-9|
Showing the most recent 10 out of 20 publications